Phase 1 Dose-Escalation Study of UGN-301 in Patients with Recurrent Non-Muscle Invasive Bladder Cancer

The primary objective of this study is to evaluate the safety and tolerability of **UGN-301** in patients with recurrent **Non-muscle Invasive Bladder Cancer (NMIBC)**. This is clinically relevant as NMIBC is a common form of bladder cancer that often recurs after initial treatment, and assessing the safety profile of new therapeutic agents is crucial for developing effective treatment options. The study aims to determine the appropriate dosage levels for further clinical development.

The clinical trial involves a total of **12 participants** diagnosed with **Non-muscle Invasive Bladder Cancer**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants were selected to include a vulnerable population, although specific criteria for vulnerability are not detailed. The trial does not specify any particular lifestyle considerations such as diet or physical activity. The selection process and any additional inclusion or exclusion criteria have not been provided by the sponsor.

The clinical trial is designed as a **Phase 1 dose-escalation study** to evaluate the safety and efficacy of UGN-301 in patients with **recurrent non-muscle invasive bladder cancer**. The trial follows a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The estimated duration of the trial spans from May 23, 2022, to June 30, 2026, allowing for comprehensive data collection and analysis over this period.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. This initial visit is crucial for ensuring that only suitable candidates are enrolled in the study. Following the screening, participants will attend regular follow-up visits, which are scheduled to monitor their response to the treatment and to collect necessary data for the study's endpoints. These visits are integral to maintaining participant safety and evaluating the treatment's impact over time. The trial will conclude with an end-of-study visit, where final assessments will be conducted to gather comprehensive data on the treatment's long-term effects.

The expected length of participant involvement in the study is determined by the trial's design and the individual response to the treatment. Participants may be subject to early termination from the study if they experience adverse effects, fail to comply with study protocols, or withdraw consent. Such conditions are in place to prioritize participant safety and the integrity of the trial data. The structured approach of this clinical trial aims to provide valuable insights into the potential benefits and risks associated with UGN-301 for patients with recurrent non-muscle invasive bladder cancer.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is a Phase 3 study, with an estimated recruitment start date of May 23, 2022, and an estimated end date of June 30, 2026. The efficacy of the investigational treatment will be assessed through predefined primary and secondary endpoints, although specific endpoints are not detailed in the provided data. The trial will follow a structured schedule for measuring and collecting efficacy data, which is typical for Phase 3 trials, but the exact methods and timepoints are not specified. The trial is categorized under trial category 1, with a trial category ID of 56214. The assessment of efficacy will be conducted in accordance with the standard practices for clinical trials of this phase and category, ensuring rigorous evaluation of the treatment's impact on the specified medical condition.